Kymab Presents Update on Lead Immunocytokine Program KY1043 at Society of Immunotherapy for Cancer 34th Annual Meeting
- KY1043, a bifunctional, PD-L1-based, IL-2Rα (CD25)-directed immunocytokine stimulates potent anti-tumor responses in vivo leading to complete regression in established tumor models
- Expanding data set continues to provide evidence for a dual mechanism-of-action of KY1043 in vitro and in vivo
- Development activities, including regulatory-enabling toxicological studies, are in progress
Cambridge, UK; November 8, 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, will today present a poster detailing an expanding body of evidence for the activity of the company’s novel immunocytokine, KY1043. The poster will be presented at the Society of Immunotherapy for Cancer (SITC) 34th Annual Meeting being held today at the Gaylord National Hotel and Convention Center, National Harbor, Fort Washington, Maryland, United States.